Scarica l'app Stockscreener
33.16
0.39%
-0.13
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALKS Giù?
Forum
Previsione
Frazionamento azionario
Alkermes Plc Borsa (ALKS) Ultime notizie
Public Sector Pension Investment Board Has $21.32 Million Stock Holdings in Alkermes plc $ALKS - MarketBeat
SNY Stock Falls After Board Suddenly Makes Leadership Change - Finviz
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales - Finviz
Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss - Finviz
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y - Finviz
CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates - Finviz
Is Alkermes plc a top pick in the sectorCEO Change & Weekly Stock Performance Updates - mfd.ru
Alkermes Completes $2.1 Billion Acquisition of Avadel Pharmaceuticals - CHEManager
Alkermes plc completes acquisition of Avadel Pharmaceuticals plc, accelerating entry into sleep medicine market - marketscreener.com
MDGL Strengthens MASH Franchise With New Genetic Approaches - Finviz
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market - BioSpace
Alkermes PLC Completes Acquisition Of Avadel Pharmaceuticals PLC, Accelerating Entry Into Sleep Medicine Market - TradingView
Alkermes PLC has successfully completed the acquisition of Avadel Pharmaceuticals plc. - Bitget
Alkermes Acquires Avadel Pharmaceuticals - Contract Pharma
Alkermes, Inc. , Alkermes, Inc and Alkermes Finance LLC Enters into Credit Agreement - marketscreener.com
Alkermes Completes Acquisition and Delisting of Avadel Pharmaceuticals - TipRanks
Alkermes Acquires Avadel to Expand Product Portfolio - Intellectia AI
Avadel Pharmaceuticals Terminates Multiple Agreements Following Alkermes Acquisition - TradingView
Alkermes (Nasdaq: ALKS) closes Avadel acquisition, adds LUMRYZ and $1.5B loans - Stock Titan
Alkermes Completes Acquisition of Avadel Pharmaceuticals, Adding LUMRYZ to Portfolio - Sleep Review
Understanding the Setup: (ALKS) and Scalable Risk - Stock Traders Daily
Alkermes to report fourth quarter and year-end financial results on Feb. 25, 2026 - MSN
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026 - Business Wire
Alkermes earnings up next as sleep strategy takes shape - Investing.com
Can Alkermes plc stock surprise with earnings upsideEarnings Growth Summary & Stock Portfolio Risk Management - mfd.ru
Irish High Court sanctions Avadel Pharmaceuticals acquisition by Alkermes - TipRanks
Alkermes (ALKS) Set to Finalize Acquisition of Avadel Pharmaceuticals - GuruFocus
Avadel Pharmaceuticals plc Announces High Court Approval of Scheme of Arrangement for Acquisition by Alkermes plc - Quiver Quantitative
Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing - The Manila Times
Irish court clears Alkermes buyout; Avadel stock trading ends Feb. 11 - Stock Titan
Alkermes Increases Offer for Avadel Acquisition - MSN
INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales - Finviz
IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus - Finviz
Alkermes plc (NASDAQ:ALKS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
History Review: Will Alkermes plc outperform its industry peersJuly 2025 Selloffs & AI Powered Market Entry Ideas - baoquankhu1.vn
Allianz Asset Management GmbH Acquires 511,702 Shares of Alkermes plc $ALKS - MarketBeat
KOD Stock Up 24% in 3 Months: Here's What You Need to Know - Finviz
Stop Loss: Is Alkermes plc benefiting from interest rate changesPrice Action & Community Trade Idea Sharing Platform - baoquankhu1.vn
Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates - Finviz
Alkermes (ALKS) Projected to Post Earnings on Wednesday - MarketBeat
Here's Why Gilead Sciences Stock Surged 21% in a Month - Finviz
Alkermes (NASDAQ:ALKS) Director Sells $2,115,684.00 in Stock - MarketBeat
Alkermes (NASDAQ:ALKS) EVP Craig Hopkinson Sells 9,000 Shares - MarketBeat
Alkermes plc (ALKS) Stock Analysis: Navigating a 29% Potential Upside in the Biopharmaceutical Sector - DirectorsTalk Interviews
Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome - Finviz
Is Alkermes (ALKS) Outperforming Other Medical Stocks This Year? - Yahoo Finance
The Technical Signals Behind (ALKS) That Institutions Follow - Stock Traders Daily
Are options traders betting on a big move in Alkermes stock? - MSN
Alkermes plc $ALKS Shares Sold by Y Intercept Hong Kong Ltd - MarketBeat
Assessing Alkermes (ALKS) Valuation After Its Recent Share Price Momentum - Yahoo Finance
FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug - Finviz
HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance - Finviz
TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth - Finviz
Are Options Traders Betting on a Big Move in Alkermes Stock? - Nasdaq
NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold - Finviz
Alkermes stock price target raised to $47 from $46 at UBS on Avadel deal - Investing.com Nigeria
Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why - Finviz
Why analysts are rating Alkermes (ALKS) a buy - MSN
Jim Cramer on Alkermes: "I Think It's a Hold, Maybe a Weak One" - Finviz
Jim Cramer on Alkermes: “I Think It’s a Hold, Maybe a Weak One” - Insider Monkey
Weekly Earnings: Is Alkermes plc benefiting from interest rate changesQuarterly Trade Report & Verified Entry Point Detection - baoquankhu1.vn
1.19%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):